AXIM Biotechnologies Reports Second Quarter 2017 Results
August 22, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter...
CEO Chris Bunka was Interviewed on Uptick Network Discussing Company’s Positive Future Progress
August 10, 2017 09:00 ET
|
Lexaria Bioscience Corp
Kelowna, BC , Aug. 10, 2017 (GLOBE NEWSWIRE) -- CEO Chris Bunka was Interviewed on Uptick Network Discussing Company’s Positive Future Progress Kelowna, BC (UPTICK Newswire – August 10, 2017) -...
AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis
August 02, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...
AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome
July 20, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...
AXIM Biotech Holds Bi-Annual Board Meeting in New York City on July 8
July 12, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, July 12, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it held its bi-annual...
CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids
July 11, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif. and TEL AVIV, Israel, July 11, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid...
CURE Pharmaceutical Expects Increased Demand for Its Enhanced Transdermal Drug Delivery Platform
July 05, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., July 05, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction Treatment
June 23, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company filed with...
AXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study
June 19, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has...
AXIM Biotech to Present at 2017 Marcum Microcap Conference in New York City
June 14, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that George Anastassov,...